Summary:
Hospital groups criticize proposed 340B changes, warning of increased burdens and uncertainty as program oversight may shift from HRSA to CMS.
Drug companies and hospitals are clashing over a new rebate model for discounted medications, which could change how hospitals pay for drugs and receive savings. A government pilot program is testing this approach with a small selection of drugs, sparking debate about costs, cash flow, and administrative hurdles. Curious about how this could impact hospitals and patients? Read on for the key details behind the controversy.
Source: 340B Rebate Models Arrive in the Form of a New Pilot Program, Nick Hut, HFMA, August 4, 2025; https://www.hfma.org/accounting-and-financial-reporting/340b-rebate-models-arrive-in-the-form-of-a-new-pilot-program/
Topics
Economics
Healthcare Process
Action Orientation
Related
The Collaboration Imperative: Why Healthcare Executives Must Unite Against an Existential ThreatPhysician Contract Negotiations: The Landscape and PredictionsGlycemic Control in Hospitalized Patients With Diabetes Mellitus: Case Series and Literature Review to Reduce Inpatient Hyperglycemia With or Without Diabetic Ketoacidosis